NCT00477906View on ClinicalTrials.gov

M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma

PHASE3UnknownINTERVENTIONAL

Enrollment

387

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2021

Conditions

Melanoma

Interventions

BIOLOGICAL

M-Vax- autologous, hapten-modified melanoma vaccine

Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster

Sponsors

Lead Sponsor

AVAX Technologies

All Listed Sponsors

lead

AVAX Technologies

INDUSTRY

NCT00477906 - M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma | Biotech Hunter | Biotech Hunter